Marino Garcia, Dianthus CEO

Ma­gen­ta sets up Di­anthus merg­er in quick, three-month about-face af­ter end­ing tri­al due to pa­tient death

Ma­gen­ta Ther­a­peu­tics will give its spot on Nas­daq to pri­vate­ly-held Di­anthus Ther­a­peu­tics af­ter a pa­tient death spurred an end to Ma­gen­ta’s clin­i­cal work and an ex­it for most of the com­pa­ny’s em­ploy­ees.

Af­ter the pa­tient death was re­port­ed in late-Jan­u­ary, Ma­gen­ta fol­lowed up a week lat­er say­ing it would go through a re­view of al­ter­na­tives, in­clud­ing a merg­er or oth­er trans­ac­tion. The com­pa­ny had set out to de­vel­op an al­ter­na­tive pre-con­di­tion­ing reg­i­men for stem cell trans­plan­ta­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.